Insulet Corp. (NASDAQ: PODD) Stock Competitors & Peer Comparison

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, ABT has a market cap of 187.4B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while ABT trades at $108.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas ABT's P/E ratio is 20.79. In terms of profitability, PODD's ROE is +0.27%, compared to ABT's ROE of +0.11%. Regarding short-term risk, PODD is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ABT's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PODD's ROE is +0.27%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, PODD is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for PODD.Check BSX-PA's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, MDT has a market cap of 120.5B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while MDT trades at $94.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas MDT's P/E ratio is 17.03. In terms of profitability, PODD's ROE is +0.27%, compared to MDT's ROE of +0.11%. Regarding short-term risk, PODD is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for PODD.Check MDT's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, SYK has a market cap of 116.2B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while SYK trades at $303.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas SYK's P/E ratio is 22.64. In terms of profitability, PODD's ROE is +0.27%, compared to SYK's ROE of +0.16%. Regarding short-term risk, PODD is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SYK's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, BSX has a market cap of 71.1B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while BSX trades at $47.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas BSX's P/E ratio is 15.42. In terms of profitability, PODD's ROE is +0.27%, compared to BSX's ROE of +0.15%. Regarding short-term risk, PODD is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for PODD.Check BSX's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, EW has a market cap of 51.8B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while EW trades at $89.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas EW's P/E ratio is 33.29. In terms of profitability, PODD's ROE is +0.27%, compared to EW's ROE of +0.10%. Regarding short-term risk, PODD is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for PODD.Check EW's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, DXCM has a market cap of 33.2B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while DXCM trades at $87.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas DXCM's P/E ratio is 34.47. In terms of profitability, PODD's ROE is +0.27%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, PODD is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for PODD.Check DXCM's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, GEHC has a market cap of 31.1B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while GEHC trades at $68.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas GEHC's P/E ratio is 15.10. In terms of profitability, PODD's ROE is +0.27%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PODD is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for PODD.Check GEHC's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, PHG has a market cap of 25.3B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while PHG trades at $25.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas PHG's P/E ratio is 14.79. In terms of profitability, PODD's ROE is +0.27%, compared to PHG's ROE of +0.10%. Regarding short-term risk, PODD is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for PODD.Check PHG's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, ZBH has a market cap of 19B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while ZBH trades at $98.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas ZBH's P/E ratio is 11.56. In terms of profitability, PODD's ROE is +0.27%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, PODD is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ZBH's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PODD's ROE is +0.27%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PODD is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ABMD's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while PEN trades at $322.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas PEN's P/E ratio is 84.16. In terms of profitability, PODD's ROE is +0.27%, compared to PEN's ROE of +0.11%. Regarding short-term risk, PODD is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for PODD.Check PEN's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PODD's ROE is +0.27%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PODD is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SWAV's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, SNN has a market cap of 12.1B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while SNN trades at $28.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas SNN's P/E ratio is 13.58. In terms of profitability, PODD's ROE is +0.27%, compared to SNN's ROE of +0.12%. Regarding short-term risk, PODD is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SNN's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while ALGN trades at $158.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas ALGN's P/E ratio is 14.46. In terms of profitability, PODD's ROE is +0.27%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, PODD is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ALGN's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, GMED has a market cap of 10.6B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while GMED trades at $78.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas GMED's P/E ratio is 17.63. In terms of profitability, PODD's ROE is +0.27%, compared to GMED's ROE of +0.12%. Regarding short-term risk, PODD is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for PODD.Check GMED's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, GKOS has a market cap of 10.5B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while GKOS trades at $177.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas GKOS's P/E ratio is -206.37. In terms of profitability, PODD's ROE is +0.27%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, PODD is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for PODD.Check GKOS's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while BIO-B trades at $381.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas BIO-B's P/E ratio is -67.15. In terms of profitability, PODD's ROE is +0.27%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, PODD is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for PODD.Check BIO-B's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while BIO trades at $386.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas BIO's P/E ratio is 41.65. In terms of profitability, PODD's ROE is +0.27%, compared to BIO's ROE of +0.03%. Regarding short-term risk, PODD is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for PODD.Check BIO's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas MASI's P/E ratio is 44.43. In terms of profitability, PODD's ROE is +0.27%, compared to MASI's ROE of +0.09%. Regarding short-term risk, PODD is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for PODD.Check MASI's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, BRKR has a market cap of 8.9B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while BRKR trades at $58.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas BRKR's P/E ratio is 29.40. In terms of profitability, PODD's ROE is +0.27%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, PODD is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for PODD.Check BRKR's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, BRKRP has a market cap of 8.6B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while BRKRP trades at $431.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas BRKRP's P/E ratio is 234.13. In terms of profitability, PODD's ROE is +0.27%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, PODD is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for PODD.Check BRKRP's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas NARI's P/E ratio is -59.24. In terms of profitability, PODD's ROE is +0.27%, compared to NARI's ROE of -0.00%. Regarding short-term risk, PODD is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for PODD.Check NARI's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, HAE has a market cap of 4.7B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while HAE trades at $102.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas HAE's P/E ratio is 20.54. In terms of profitability, PODD's ROE is +0.27%, compared to HAE's ROE of +0.11%. Regarding short-term risk, PODD is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for PODD.Check HAE's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, LIVN has a market cap of 4.5B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while LIVN trades at $81.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas LIVN's P/E ratio is 19.46. In terms of profitability, PODD's ROE is +0.27%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, PODD is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for PODD.Check LIVN's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while ITGR trades at $126.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas ITGR's P/E ratio is 19.76. In terms of profitability, PODD's ROE is +0.27%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, PODD is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ITGR's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, IRTC has a market cap of 4.1B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while IRTC trades at $123.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas IRTC's P/E ratio is -287.05. In terms of profitability, PODD's ROE is +0.27%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, PODD is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for PODD.Check IRTC's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PODD's ROE is +0.27%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, PODD is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for PODD.Check AXNX's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while TMDX trades at $89.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas TMDX's P/E ratio is 45.68. In terms of profitability, PODD's ROE is +0.27%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, PODD is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for PODD.Check TMDX's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while AXGN trades at $48.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas AXGN's P/E ratio is 127.05. In terms of profitability, PODD's ROE is +0.27%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, PODD is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for PODD.Check AXGN's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while NEOG trades at $11.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas NEOG's P/E ratio is 42.25. In terms of profitability, PODD's ROE is +0.27%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, PODD is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for PODD.Check NEOG's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, UFPT has a market cap of 2.2B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while UFPT trades at $288.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas UFPT's P/E ratio is 29.50. In terms of profitability, PODD's ROE is +0.27%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, PODD is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for PODD.Check UFPT's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while ESTA trades at $74.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas ESTA's P/E ratio is -58.96. In terms of profitability, PODD's ROE is +0.27%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, PODD is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ESTA's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, NVCR has a market cap of 2.1B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while NVCR trades at $17.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas NVCR's P/E ratio is -13.80. In terms of profitability, PODD's ROE is +0.27%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, PODD is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for PODD.Check NVCR's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PODD's ROE is +0.27%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PODD is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for PODD.Check NUVA's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, BFLY has a market cap of 2B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while BFLY trades at $7.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas BFLY's P/E ratio is -30.67. In terms of profitability, PODD's ROE is +0.27%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, PODD is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for PODD.Check BFLY's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while INSP trades at $63.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas INSP's P/E ratio is 27.76. In terms of profitability, PODD's ROE is +0.27%, compared to INSP's ROE of +0.18%. Regarding short-term risk, PODD is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for PODD.Check INSP's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while CNMD trades at $49.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas CNMD's P/E ratio is 10.84. In terms of profitability, PODD's ROE is +0.27%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, PODD is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for PODD.Check CNMD's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while ATEC trades at $9.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas ATEC's P/E ratio is -157.50. In terms of profitability, PODD's ROE is +0.27%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, PODD is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ATEC's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, TNDM has a market cap of 1.4B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while TNDM trades at $19.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas TNDM's P/E ratio is -21.40. In terms of profitability, PODD's ROE is +0.27%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, PODD is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for PODD.Check TNDM's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PODD's ROE is +0.27%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PODD is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for PODD.Check HSKA's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while IART trades at $16.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas IART's P/E ratio is 7.08. In terms of profitability, PODD's ROE is +0.27%, compared to IART's ROE of -0.01%. Regarding short-term risk, PODD is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for PODD.Check IART's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while PRCT trades at $22.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas PRCT's P/E ratio is -11.73. In terms of profitability, PODD's ROE is +0.27%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, PODD is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for PODD.Check PRCT's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while AORT trades at $25.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas AORT's P/E ratio is 42.63. In terms of profitability, PODD's ROE is +0.27%, compared to AORT's ROE of -0.01%. Regarding short-term risk, PODD is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for PODD.Check AORT's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas AVNS's P/E ratio is 27.77. In terms of profitability, PODD's ROE is +0.27%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, PODD is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for PODD.Check AVNS's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, LMRI has a market cap of 1.2B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while LMRI trades at $12.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas LMRI's P/E ratio is -23.70. In terms of profitability, PODD's ROE is +0.27%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, PODD is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for PODD.Check LMRI's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas SILK's P/E ratio is -18.96. In terms of profitability, PODD's ROE is +0.27%, compared to SILK's ROE of -0.35%. Regarding short-term risk, PODD is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SILK's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while IRMD trades at $83.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas IRMD's P/E ratio is 43.51. In terms of profitability, PODD's ROE is +0.27%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PODD is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for PODD.Check IRMD's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas FNA's P/E ratio is -19.83. In terms of profitability, PODD's ROE is +0.27%, compared to FNA's ROE of -0.35%. Regarding short-term risk, PODD is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for PODD.Check FNA's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while ENOV trades at $18.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas ENOV's P/E ratio is 5.31. In terms of profitability, PODD's ROE is +0.27%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, PODD is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ENOV's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, BVS has a market cap of 953.2M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while BVS trades at $14.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas BVS's P/E ratio is 18.51. In terms of profitability, PODD's ROE is +0.27%, compared to BVS's ROE of +0.28%. Regarding short-term risk, PODD is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for PODD.Check BVS's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, CBLL has a market cap of 937.9M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while CBLL trades at $24.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas CBLL's P/E ratio is -14.05. In terms of profitability, PODD's ROE is +0.27%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, PODD is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for PODD.Check CBLL's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, AHCO has a market cap of 883M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while AHCO trades at $6.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas AHCO's P/E ratio is 13.24. In terms of profitability, PODD's ROE is +0.27%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, PODD is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for PODD.Check AHCO's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, AVR has a market cap of 879M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while AVR trades at $9.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas AVR's P/E ratio is -4.66. In terms of profitability, PODD's ROE is +0.27%, compared to AVR's ROE of -0.78%. Regarding short-term risk, PODD is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for PODD.Check AVR's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, BBNX has a market cap of 873.7M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while BBNX trades at $19.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas BBNX's P/E ratio is -11.77. In terms of profitability, PODD's ROE is +0.27%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, PODD is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for PODD.Check BBNX's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, INMD has a market cap of 857M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while INMD trades at $14.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas INMD's P/E ratio is 10.35. In terms of profitability, PODD's ROE is +0.27%, compared to INMD's ROE of +0.12%. Regarding short-term risk, PODD is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for PODD.Check INMD's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas CSII's P/E ratio is -20.83. In terms of profitability, PODD's ROE is +0.27%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PODD is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for PODD.Check CSII's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, SIBN has a market cap of 820.5M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while SIBN trades at $18.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas SIBN's P/E ratio is -54.41. In terms of profitability, PODD's ROE is +0.27%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, PODD is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SIBN's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, VREX has a market cap of 779.3M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while VREX trades at $18.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas VREX's P/E ratio is 19.48. In terms of profitability, PODD's ROE is +0.27%, compared to VREX's ROE of +0.05%. Regarding short-term risk, PODD is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for PODD.Check VREX's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, SSII has a market cap of 682.4M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while SSII trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas SSII's P/E ratio is -66.51. In terms of profitability, PODD's ROE is +0.27%, compared to SSII's ROE of -0.27%. Regarding short-term risk, PODD is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SSII's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas SRDX's P/E ratio is -34.66. In terms of profitability, PODD's ROE is +0.27%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, PODD is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SRDX's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, CTKB has a market cap of 607M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while CTKB trades at $4.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas CTKB's P/E ratio is -24.90. In terms of profitability, PODD's ROE is +0.27%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, PODD is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for PODD.Check CTKB's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas APEN's P/E ratio is -9.43. In terms of profitability, PODD's ROE is +0.27%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PODD is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for PODD.Check APEN's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, KIDS has a market cap of 575.6M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while KIDS trades at $22.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas KIDS's P/E ratio is -18.99. In terms of profitability, PODD's ROE is +0.27%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, PODD is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for PODD.Check KIDS's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, DCTH has a market cap of 568.9M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while DCTH trades at $16.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas DCTH's P/E ratio is 1648.00. In terms of profitability, PODD's ROE is +0.27%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, PODD is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for PODD.Check DCTH's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, PODD's ROE is +0.27%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, PODD is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ZIMV's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, CERS has a market cap of 521.9M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while CERS trades at $2.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas CERS's P/E ratio is -51.70. In terms of profitability, PODD's ROE is +0.27%, compared to CERS's ROE of -0.10%. Regarding short-term risk, PODD is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for PODD.Check CERS's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, NPCE has a market cap of 508M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while NPCE trades at $14.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas NPCE's P/E ratio is -26.14. In terms of profitability, PODD's ROE is +0.27%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, PODD is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for PODD.Check NPCE's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, TCMD has a market cap of 493.3M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while TCMD trades at $21.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas TCMD's P/E ratio is 20.25. In terms of profitability, PODD's ROE is +0.27%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, PODD is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for PODD.Check TCMD's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, SGHT has a market cap of 454.3M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while SGHT trades at $8.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas SGHT's P/E ratio is -14.91. In terms of profitability, PODD's ROE is +0.27%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, PODD is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for PODD.Check SGHT's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, CARL has a market cap of 424.1M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while CARL trades at $15.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas CARL's P/E ratio is -10.91. In terms of profitability, PODD's ROE is +0.27%, compared to CARL's ROE of -0.38%. Regarding short-term risk, PODD is more volatile compared to CARL. This indicates higher risk in terms of short-term price fluctuations for PODD.Check CARL's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, PACB has a market cap of 419.3M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while PACB trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas PACB's P/E ratio is -3.29. In terms of profitability, PODD's ROE is +0.27%, compared to PACB's ROE of -49.62%. Regarding short-term risk, PODD is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for PODD.Check PACB's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, CLPT has a market cap of 418.7M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while CLPT trades at $13.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas CLPT's P/E ratio is -11.83. In terms of profitability, PODD's ROE is +0.27%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, PODD is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for PODD.Check CLPT's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, SENS has a market cap of 402.5M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while SENS trades at $9.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas SENS's P/E ratio is -4.32. In terms of profitability, PODD's ROE is +0.27%, compared to SENS's ROE of -1.66%. Regarding short-term risk, PODD is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for PODD.Check SENS's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, OFIX has a market cap of 375.5M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while OFIX trades at $9.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas OFIX's P/E ratio is -6.05. In terms of profitability, PODD's ROE is +0.27%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, PODD is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for PODD.Check OFIX's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, CATX has a market cap of 358.1M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while CATX trades at $3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas CATX's P/E ratio is -2.36. In terms of profitability, PODD's ROE is +0.27%, compared to CATX's ROE of -0.42%. Regarding short-term risk, PODD is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for PODD.Check CATX's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, TMCI has a market cap of 312M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while TMCI trades at $4.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas TMCI's P/E ratio is -5.12. In terms of profitability, PODD's ROE is +0.27%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, PODD is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for PODD.Check TMCI's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas SMLR's P/E ratio is 3.92. In terms of profitability, PODD's ROE is +0.27%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, PODD is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for PODD.Check SMLR's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, TLSI has a market cap of 307.9M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while TLSI trades at $5.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas TLSI's P/E ratio is -2.98. In terms of profitability, PODD's ROE is +0.27%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, PODD is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for PODD.Check TLSI's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, CV has a market cap of 299.3M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while CV trades at $5.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas CV's P/E ratio is -2.40. In terms of profitability, PODD's ROE is +0.27%, compared to CV's ROE of -1.78%. Regarding short-term risk, PODD is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for PODD.Check CV's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, RCEL has a market cap of 278.2M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while RCEL trades at $11.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas RCEL's P/E ratio is -7.78. In terms of profitability, PODD's ROE is +0.27%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, PODD is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for PODD.Check RCEL's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, RXST has a market cap of 263.9M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while RXST trades at $6.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas RXST's P/E ratio is -5.64. In terms of profitability, PODD's ROE is +0.27%, compared to RXST's ROE of -0.17%. Regarding short-term risk, PODD is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for PODD.Check RXST's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, PROF has a market cap of 250.4M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while PROF trades at $6.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas PROF's P/E ratio is -7.03. In terms of profitability, PODD's ROE is +0.27%, compared to PROF's ROE of -0.56%. Regarding short-term risk, PODD is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for PODD.Check PROF's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, INFU has a market cap of 246M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while INFU trades at $12.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas INFU's P/E ratio is 29.73. In terms of profitability, PODD's ROE is +0.27%, compared to INFU's ROE of +0.15%. Regarding short-term risk, PODD is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for PODD.Check INFU's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas MGRM's P/E ratio is -12.00. In terms of profitability, PODD's ROE is +0.27%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, PODD is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for PODD.Check MGRM's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, ELMD has a market cap of 232.1M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while ELMD trades at $28.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas ELMD's P/E ratio is 21.40. In terms of profitability, PODD's ROE is +0.27%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, PODD is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for PODD.Check ELMD's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PODD's ROE is +0.27%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PODD is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for PODD.Check NVRO's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, STIM has a market cap of 200.4M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while STIM trades at $2.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas STIM's P/E ratio is -6.55. In terms of profitability, PODD's ROE is +0.27%, compared to STIM's ROE of -1.51%. Regarding short-term risk, PODD is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for PODD.Check STIM's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas BSGM's P/E ratio is -5.81. In terms of profitability, PODD's ROE is +0.27%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, PODD is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for PODD.Check BSGM's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, LUCD has a market cap of 179.2M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while LUCD trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas LUCD's P/E ratio is -2.54. In terms of profitability, PODD's ROE is +0.27%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, PODD is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for PODD.Check LUCD's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas MDGS's P/E ratio is -0.27. In terms of profitability, PODD's ROE is +0.27%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, PODD is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for PODD.Check MDGS's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas QIPT's P/E ratio is -15.87. In terms of profitability, PODD's ROE is +0.27%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PODD is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for PODD.Check QIPT's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, FOCL has a market cap of 155.6M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while FOCL trades at $4.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas FOCL's P/E ratio is -4.01. In terms of profitability, PODD's ROE is +0.27%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, PODD is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for PODD.Check FOCL's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, QSI has a market cap of 151.5M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while QSI trades at $0.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas QSI's P/E ratio is -1.67. In terms of profitability, PODD's ROE is +0.27%, compared to QSI's ROE of -0.47%. Regarding short-term risk, PODD is more volatile compared to QSI. This indicates higher risk in terms of short-term price fluctuations for PODD.Check QSI's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, INGN has a market cap of 146.7M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while INGN trades at $5.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas INGN's P/E ratio is -5.96. In terms of profitability, PODD's ROE is +0.27%, compared to INGN's ROE of -0.13%. Regarding short-term risk, PODD is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for PODD.Check INGN's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, QTRX has a market cap of 126.7M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while QTRX trades at $2.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas QTRX's P/E ratio is -1.06. In terms of profitability, PODD's ROE is +0.27%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, PODD is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for PODD.Check QTRX's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas ICAD's P/E ratio is -20.37. In terms of profitability, PODD's ROE is +0.27%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, PODD is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for PODD.Check ICAD's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, LNSR has a market cap of 105.4M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while LNSR trades at $8.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas LNSR's P/E ratio is 8.76. In terms of profitability, PODD's ROE is +0.27%, compared to LNSR's ROE of +103.80%. Regarding short-term risk, PODD is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for PODD.Check LNSR's competition here

Insulet Corp. (NASDAQ: PODD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PODD stands at 10.2B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, PODD is priced at $147.48 on the NASDAQ, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PODD currently has a P/E ratio of 25.12, whereas HJLI's P/E ratio is N/A. In terms of profitability, PODD's ROE is +0.27%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, PODD is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for PODD.Check HJLI's competition here